Apyx Medical Announces Approval, Commercial Roll Out Of Apyx One Console, Single-Use Handpieces In South Korea

Apyx Medical Corporation (NASDAQ:APYX) (the "Company" or "Apyx Medical") the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body Contouring System™ (AYON), today announced the approval and commercial launch of the Apyx One console and single-use handpieces in South Korea following the recent regulatory approval by the Ministry of Food and Drug Safety (MFDS). The Company plans to start shipping Apyx One consoles and single-use handpieces to South Korea to fill initial orders starting in the fourth quarter of 2025.

The Apyx One console is a multi-functional generator incorporating an advanced 3-in-1 energy system that enables plastic and cosmetic surgeons to utilize Renuvion technology, together with full monopolar and bipolar energy. Key features of the Apyx One console include adaptive and intuitive touch screens, procedural presets by body part, quantification of energy delivered to a body area, and an advanced gas system that measures and monitors gas volume and usage.